4d Molecular Therapeutics Stock News

4D Molecular Therapeutics (NASDAQ:FDMT) was upgraded by Zacks Investment Research from a hold rating to a buy rating in a report released on Wednesday, Zacks.com reports. The brokerage presently has a $23.00 target price on the stock. Zacks Investment Researchs target price would suggest a potential upside of 10.79% from the companys current price. According []

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) gapped up before the market opened on Tuesday . The stock had previously closed at $21.42, but opened at $22.02. 4D Molecular Therapeutics shares last traded at $22.55, with a volume of 1,131 shares traded. Separately, Zacks Investment Research raised 4D Molecular Therapeutics from a hold rating to []

Zacks Investment Research upgraded shares of 4D Molecular Therapeutics (NASDAQ:FDMT) from a hold rating to a buy rating in a report published on Tuesday, Zacks.com reports. They currently have $24.00 price target on the stock. According to Zacks, 4D Molecular Therapeutics Inc. is a clinical-stage gene therapy company which develops product candidates using its targeted []

State Street Corp increased its holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) by 54.9% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 165,492 shares of the companys stock after buying an additional 58,659 shares during the period. State Street Corps holdings in 4D Molecular Therapeutics were []

EMERYVILLE, Calif., Nov. 23, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced that management will participate in a fireside chat at the Evercore ISI HealthCONx 2021 Conference. The fireside chat will take place on Thursday, December 2 nd , 2021 at 10:55 a.m. ET.

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) shares gapped down prior to trading on Friday . The stock had previously closed at $24.15, but opened at $22.79. 4D Molecular Therapeutics shares last traded at $22.79, with a volume of 612 shares changing hands. Separately, Zacks Investment Research raised 4D Molecular Therapeutics from a hold rating to a []

The stock price of 4D Molecular Therapeutics Inc (NASDAQ: FDMT) increased by over 13% during intraday trading today. This is why it happened.

EMERYVILLE, Calif., Oct. 10, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene thera

Initiation of 4D-150 Phase 1/2 clinical trial sites expected before year-end Initiation of 4D-150 Phase 1/2 clinical trial sites expected before year-end

EMERYVILLE, Calif., Sept. 29, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene ther

EMERYVILLE, Calif., Sept. 24, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene ther

FDMT, BOOM, FRPT, GEL and HTBK have been added to the Zacks Rank #5 (Strong Sell) List on July 23, 2021.

EMERYVILLE, Calif., June 24, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene thera

EMERYVILLE, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therap

EMERYVILLE, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therap